Pituitary-adrenocortical hyperfunction and intolerance to fluvoxamine, a selective serotonin uptake inhibitor

Area of Science:

• Psychopharmacology
• Neuroscience
• Clinical Psychiatry

Background:

• The dexamethasone suppression test (DST) is a biological marker used in psychiatric research.
• Serotonin uptake inhibiting antidepressants, like fluvoxamine, are commonly prescribed.
• Understanding differential drug responses based on biological markers is crucial for personalized medicine.

Purpose of the Study:

• To investigate the relationship between dexamethasone suppression test (DST) status and the incidence of side effects from fluvoxamine treatment.
• To determine if DST nonsuppressors exhibit a higher rate of intolerable side effects to fluvoxamine compared to DST suppressors.

Main Methods:

• A cohort of patients undergoing treatment with fluvoxamine was assessed.
• Patients were categorized into two groups based on their performance on the dexamethasone suppression test (DST): suppressors and nonsuppressors.
• Incidence of intolerable side effects during fluvoxamine treatment was recorded and compared between the two groups.

Main Results:

• Five out of nine (56%) patients who were nonsuppressors on the DST developed intolerable side effects.
• In contrast, only three out of 24 (13%) patients who were suppressors on the DST reported intolerable side effects.
• A significantly higher proportion of DST nonsuppressors experienced adverse events during fluvoxamine therapy.

Conclusions:

• Dexamethasone suppression test (DST) nonsuppressor status may be associated with an increased risk of experiencing intolerable side effects from fluvoxamine.
• These findings suggest that DST status could potentially inform treatment decisions regarding fluvoxamine or similar antidepressants.
• Further research is warranted to elucidate the mechanisms underlying this differential response and to validate these clinical observations.